24 Hrs
Source:
المصري اليوم
mRNA Vaccine Offers Hope for Melanoma
Merc and Moderna announced the successful development of a personalized mRNA-based vaccine for the treatment of melanoma, one of the most dangerous types of skin cancer, during advanced clinical trials. The Phase 3 results showed that using the vaccine alongside the immunotherapy drug Keytruda significantly reduces the risk of disease recurrence and spread, with trials recording a 49% decrease in the likelihood of melanoma returning and a 59% reduction in cancer spreading to other organs. The treatment relies on analyzing each patient's tumor genetics and designing a tailored vaccine targeting the unique mutations. Broad availability for patients may be possible by early 2027 after completing the regulatory process and receiving FDA approval. This breakthrough has the potential to transform melanoma treatment methods and improve patient outcomes.
Size: 120%Text Size
Notice: This Is an AI-Generated Summary
Comments (0)